Want to see EMMA full AI Analyst Report?
Top Page
Emmaus Life Sciences
(OTC:EMMA)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.04
▲(310.00% Upside)
Action:Reiterated
Date:10/03/26
The score is held down primarily by elevated financial risk—persistent net losses and a severely stressed balance sheet with negative equity—despite strong gross margins and a recent improvement to positive operating/free cash flow. Technicals are modestly supportive, but valuation is constrained by negative earnings and no dividend data.
Positive Factors
Revenue Growth
Revenue growth of roughly 29% indicates expanding demand for the company’s commercial offering and stronger market reach. If sustained, this top-line momentum can provide greater operating leverage, support reinvestment, and improve the foundation for future earnings development.
Negative Factors
Negative Equity and Debt
Severely negative equity and meaningful debt leave the company with a thin financial cushion and limited balance-sheet flexibility. This structure can constrain investment capacity and increase exposure to refinancing or dilution if operating performance weakens.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Revenue growth of roughly 29% indicates expanding demand for the company’s commercial offering and stronger market reach. If sustained, this top-line momentum can provide greater operating leverage, support reinvestment, and improve the foundation for future earnings development.
Read all positive factors
Emmaus Life Sciences (EMMA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.96M
Dividend YieldN/A
Average Volume (3M)132.75K
Price to Earnings (P/E)―
Beta (1Y)-1.66
Revenue Growth10.98%
EPS Growth-72.08%
CountryUS
Employees33
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.09
Shares Outstanding70,188,260
10 Day Avg. Volume21,252
30 Day Avg. Volume132,753
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.01
Price to Sales (P/S)0.07
P/FCF Ratio-69.38
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Emmaus Life Sciences Business Overview & Revenue Model
Company Description
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical enterprise dedicated to the discovery, development, commercialization, and sale of treatments and therapies, primarily addressing rare and orphan diseases across the United States ...
How the Company Makes Money
Emmaus Life Sciences primarily makes money by selling its prescription drug Endari (L-glutamine oral powder). Revenue is generated from product sales fulfilled through pharmaceutical distribution and dispensing channels, including specialty pharma...
Emmaus Life Sciences Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
22
Negative
Cash Flow
46
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Jun 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.53M | 12.45M | 16.65M | 29.60M | 18.39M | 20.61M |
| Gross Profit | 14.54M | 11.60M | 15.45M | 28.25M | 15.80M | 17.30M |
| EBITDA | 3.40M | -310.00K | -910.00K | 3.62M | -5.50M | -12.76M |
| Net Income | -6.02M | -7.49M | -6.45M | -3.73M | -10.63M | -15.95M |
Balance Sheet | ||||||
| Total Assets | 16.37M | 21.44M | 23.60M | 35.18M | 48.23M | 56.73M |
| Cash, Cash Equivalents and Short-Term Investments | 2.81M | 2.13M | 1.39M | 2.55M | 2.02M | 2.28M |
| Total Debt | 30.52M | 32.56M | 32.96M | 32.65M | 30.82M | 29.91M |
| Total Liabilities | 82.55M | 85.04M | 80.08M | 82.94M | 82.32M | 78.18M |
| Stockholders Equity | -66.18M | -63.61M | -56.48M | -47.76M | -34.09M | -21.45M |
Cash Flow | ||||||
| Free Cash Flow | 3.96M | -12.00K | -2.30M | -1.52M | -5.10M | -1.33M |
| Operating Cash Flow | 3.97M | -11.00K | -2.29M | -1.50M | -5.07M | -1.25M |
| Investing Cash Flow | 1.58M | 2.17M | 2.50M | -432.00K | -2.39M | -6.38M |
| Financing Cash Flow | -3.60M | -1.43M | -1.35M | 2.48M | 7.23M | 7.41M |
Emmaus Life Sciences Technical Analysis
Neutral
0.01
Price Trends
0.04
Positive
0.02
Positive
0.02
Positive
Market Momentum
<0.01
Positive
40.66
Neutral
12.15
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EMMA, the sentiment is Neutral. The current price of 0.01 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.04, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 40.66 is Neutral, neither overbought nor oversold. The STOCH value of 12.15 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for EMMA.
Emmaus Life Sciences Risk Analysis
Emmaus Life Sciences disclosed 32 risk factors in its most recent earnings report. Emmaus Life Sciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Emmaus Life Sciences Peers Comparison
UnderperformOutperform
Sector (51)
EMMA
Emmaus Life Sciences
0.04
0.03
281.82%
SCNI
Scinai Immunotherapeutics
1.33
-12.22
-90.18%
ADTX
Aditxt
0.04
-16,736.52
-100.00%
DRMA
Dermata Therapeutics
1.11
-4.28
-79.46%
CERO
CERo Therapeutics Holdings
0.01
-5.38
-99.81%
CDT
CDT Equity
0.99
-41,489.01
-100.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.